首页> 外文会议>World biomaterials congress >The tissue-engineered human cornea as a model to study the contribution of the integrin-mediated signal transaction pathways activated during corneal wound healing
【24h】

The tissue-engineered human cornea as a model to study the contribution of the integrin-mediated signal transaction pathways activated during corneal wound healing

机译:组织工程化的人类角膜作为研究角膜伤口愈合过程中激活的整合素介导的信号交易途径的贡献的模型

获取原文

摘要

Introduction: The cornea is localized at the outer surface of the eye. It is a transparent organ and highly specialized that is continually subjected to abrasive forces and occasional mechanical or chemical trauma because of its anatomical localization. A complete reepithelialization and the reorganization of a mature smooth stratified epithelium are essential in restoring the imaging properties of the cornea. We recently succeeded in tissue-engineering human cornea substitutes that mimic their in vivo counterpart in terms of cell phenotype and tissue architecture. Upon injury, the extracellular matrix (ECM) rapidly changes to promote wound healing through its interactions with integrins. We hypothesize that the remodelling of the ECM occurring during comeal wound healing causes the activation of very specific signal transaction mediators that favor faster closure profiling analyses provided evidence that wound closure is dependent in part on signalization by the PI3K/AM transaction pathway. Our goal is to proceed to the pharmacological inhibition or activation of the PI3K/Akt mediators Akt and CREB using the human tissue-engineered cornea (hTECs) as a model. Materials and Methods: The self-assembly approach was used to create hTECs as previously described They were wounded with a 8-mm diameter biopsy punch and deposited on another reconstructed human comeal slroma to allow wound closure on a natural ECM. The wounded tissues were then incubated with or without C646 (a CREB inhibitor) or with or without SC79 (an AKT activator). DMSO (the vehicle) was used alone as a negative control. Closure of the wounds was monitored over a period of 5 days to determine whether Akt activation and CREB inhibition will improve closure of the wounds. Results and Discussion: Data from the gene and protein profiling analyses indicate that important alterations in the expression of a few mediators is occurring primarily in the PI3K/AM pathways in response to the ECM remodeling taking place during wound healing of hTECs. Pharmacological inhibition of CREB with C646 considerably accelerated wound closure compared to control. Moreover, maintaining the wounded hTEC in the presence of both C646 and SC79 led to complete closure of the wounds in a much shorter time than C646 alone or the untreated controls. Conclusion: By simultaneously blocking the activation of CREB and enhancing the activation of Akt, we considerably altered the migratory properties of the comeal epithelial cells and substantially accelerated wound closure of injured hTEC thereby validating the use of the tissue-engineered human cornea as an outstanding model to study comeal wound healing. We hope this study will lead to progress in the clinical field of comeal blindness.
机译:简介:角膜位于眼睛的外表面。它是透明的器官,高度专业化,由于其解剖学上的局限性,因此不断受到磨蚀力和偶然的机械或化学损伤。完整的再上皮化和成熟的光滑分层上皮的重组对于恢复角膜的成像特性至关重要。我们最近在组织工程化人类角膜替代品方面取得了成功,该替代品在细胞表型和组织结构方面模仿了它们的体内对应物。损伤后,细胞外基质(ECM)通过与整联蛋白的相互作用而迅速变化,从而促进伤口愈合。我们假设,在彗形伤口愈合期间发生的ECM重塑会引起非常特异性的信号交易介体的激活,这有利于进行更快的闭合分析,前提是证据表明伤口闭合部分取决于PI3K / AM交易途径的信号传导。我们的目标是使用人体组织工程角膜(hTECs)作为模型,对PI3K / Akt介体Akt和CREB进行药理学抑制或激活。材料和方法:自组装方法用于创建hTEC,如前所述。将它们用8毫米直径的活检打孔器打伤,并沉积在另一个重建的人类彗星浆膜瘤上,以允许在自然ECM上闭合伤口。然后在有或没有C646(CREB抑制剂)或有或没有SC79(AKT激活剂)的情况下孵育受伤的组织。 DMSO(媒介物)单独用作阴性对照。在5天的时间内监测伤口的闭合,以确定Akt激活和CREB抑制是否将改善伤口的闭合。结果与讨论:来自基因和蛋白质谱分析的数据表明,响应于hTECs伤口愈合期间发生的ECM重塑,一些介体表达的重要改变主要发生在PI3K / AM途径中。与对照相比,C646对CREB的药理抑制作用大大加速了伤口闭合。此外,与C646单独治疗或未治疗的对照组相比,在C646和SC79均存在的情况下维持受伤的hTEC可以在短得多的时间内完全闭合伤口。结论:通过同时阻断CREB的激活和增强Akt的激活,我们大大改变了彗星上皮细胞的迁移特性,并显着加速了受损hTEC的伤口闭合,从而验证了组织工程化的人类角膜作为杰出模型的应用研究彗星伤口的愈合。我们希望这项研究将在彗星失明的临床领域取得进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号